Mutual Fund Biotechnology in Sberbank - share price, dynamics

0

The Sberbank Asset Management service has been operating since 1996.
It was originally called Troika Dialog. Today, it is one of the largest, dynamically growing and reliable companies specializing in asset management throughout Russia. This article will focus on the possibilities of collective investment. Mutual Fund Biotechnology in Sberbank - the price of the share and the dynamics will be discussed below.

Benefits of investing in mutual funds

The main specifics of Sberbank Asset Management is the management of collective deposits (mutual investment funds).

By investing in the Biotechnology Mutual Fund in Sberbank, access to other Sberbank Mutual Funds , but all asset management responsibilities fall on the shoulders of the company's professionals. They have a good stock of experience and knowledge, which has been repeatedly confirmed by the recognition of international experts. The meaning of the work of portfolio managers is to choose the right strategy and further manage the funds in a combined form received from shareholders, based on the principles of the chosen method.

Here are the obvious prospects:

  1. Investments are at the disposal of specialized managers.
  2. Information about the current state of the mutual fund is available both in the printed edition and on the website.
  3. There is an opportunity for diversification.
  4. The situation can be controlled remotely.

Mutual investment fund Biotechnology in Sberbank - share price

Growth dynamics for a given period - on page .

Features of investing in biotechnology

Mutual Fund Biotechnology provides an opportunity to invest in the growing and profitable area of ​​biotechnology. Here we look at the dynamics of the NASDAQ Biotechnology Index, which includes securities of the largest biotech and pharmaceutical corporations in the portfolio, focused on the development of the latest generation of drugs. And investors contribute investment funds to the US iShares NASDAQBiotechnology ETF.

According to many experts in the field, the biotech spectrum is not concerned with the risks and concomitant factors of the economy associated with it. Therefore, this direction of investment is considered quite rational and promising. After all, companies specializing in biotechnology and the production of effective drugs are becoming more and more popular, as global environmental and health trends are actively deteriorating.

However, like any other type of investment, there are risks involved. Therefore, Sberbank makes the main investment in the sectoral index, which gives the largest increase, according to analytical data.

Prospects for Mutual Investment Fund Biotechnology

In Sberbank of Russia, the Mutual Fund of Biotechnology was formed in May 2015. And today Asset Management invests in only one asset. According to forecasts of analytical accumulation, the portfolio should become more expanded, which will make it possible to receive a good income.

In turn, Sberbank specialists are inclined to believe that the biotechnological industry can go under the control of state regulation. This fact is explained by the importance of the results of work in the field of development. And they, as you know, are not always profitable from a commercial point of view.

A mutual fund makes it possible to invest even small amounts in this spectrum. For clarity, the minimum deposit can be only 15,000 rubles or 1,000 rubles butt through the Personal Account. Plus, the program does not exclude the possibility of making repeated deposits, in the amount of one and a half thousand rubles. As for the risks, they are all related exclusively to the US market stability. Therefore, portfolio specialists advise making investments either for a long-term or for a medium-long period, which ranges from 1 to 3 years. More is possible, but less is not desirable.

The prospect of profitability of investing in this mutual fund, according to experts' forecasts, is also confirmed by a stable trend in the profitability of the largest biotechnology companies:

  • Keryx Biopharma - 78%;
  • curis inc. — 78%;
  • AbbVie - 44%;
  • Gilead Sciences Shing - 43%.

The biotech spectrum in the general American economy has recently become very active. In the five-year period alone, the profit was 277%, and the NASDAQ Biotechnology Index increased by 18% annually.

How to become a member, reviews

Since the mutual fund Sberbank Biotechnology is still quite young, reviews about it are not unambiguous. Yes, and the real values ​​\u200b\u200bare not yet displayed. In order to become an investor, you need to contact a bank branch that provides investment services. A list of such bank branches can be requested by calling the Sberbank hotline 8 800 555 55 00 , or you can find out on the website . For consultations - 8 800 100 31 11. At the branch of Sberbank, you must go through the following procedure:

  1. Create a portfolio. It is desirable to give preference to the Mutual Fund of Biotechnologies, or to select several optimal Mutual Funds. If necessary, the manager will help with the choice.
  2. Fill out an application for the purchase of shares. Before that, you should calculate the amount of the first installment and subsequent deposits, as well as the timing of possible investment.
  3. Enter personal data to open an account in order to receive funds from profit. Passport must be presented.
  4. Make payment for units by transfer or in cash. During the operation, no commission is charged.

In the process of closing (repaying) a mutual fund of Sberbank Biotechnology, one should take into account the collection of a certain amount of money, which is called a discount.

This size is:

  • 2%, provided that the shareholder has owned them for no more than six months;
  • 1% - from six months to 2 years;
  • 0% - more than 2 years.

IT MAY BE INTERESTING